Orion OYJ (OTCMKTS:ORINY) Shares Gap Down - Time to Sell?

Key Points

• Orion OYJ shares gapped down about 7.4%, opening at $37.9875 after a prior close of $41.04, with very light volume of 105 shares.
• Analyst action: Danske downgraded the stock from Buy to Hold, and the consensus rating is currently Hold (1 Buy, 2 Holds).
• Fundamentals remain solid — market cap $10.72B, PE 18.62, debt/equity 0.09, and recent quarter EPS $1.08 with a net margin of 26.68% and ROE of 47.67%.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $41.04, but opened at $37.9875. Orion OYJ shares last traded at $37.9875, with a volume of 105 shares.

Analyst Ratings Changes

Separately, Danske lowered shares of Orion OYJ from a "buy" rating to a "hold" rating in a report on Thursday, January 15th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Orion OYJ presently has a consensus rating of "Hold".

Orion OYJ Stock Down 7.4%

The company has a market capitalization of $10.72 billion, a PE ratio of 18.62 and a beta of 0.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.58 and a current ratio of 2.40. The company's 50-day moving average is $39.84 and its 200 day moving average is $37.71.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported $1.08 earnings per share (EPS) for the quarter. The firm had revenue of $809.41 million for the quarter. Orion OYJ had a net margin of 26.68% and a return on equity of 47.67%. As a group, analysts anticipate that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current year.

About Orion OYJ

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company's core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion's product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.